

EFFICACY AND SAFETY OF ANTIBACTERIAL THERAPY IN CASES OF NON-SEVERE COMMUNITY-ACQUIRED PNEUMONIA

***O. Ya. Dzyublyk, R. E. Sukhin, O. O. Mukhin,
S. S. Simonov, V. V. Dyachenko,
N. M. Nedlinska, V. G. Slabchenko,
G. B. Kapitan, V. Ya. Klyagin, M. G. Sobko,
T. M. Yengalicheva, L. V. Chechel,
E. M. Tumarova, L. I. Parhotyk***

Summary

The results of conducted study demonstrated that both regimens of antibacterial chemotherapy — aminopenicillin (amoxicillin) or new macrolide (azithromycin, midecamycin or clarithromycin) monotherapy in cases of non-severe community-acquired pneumonia without concomitant disease (patients less than 60 years old), and amoxicillin in combination with clavulanic acid or third generation fluoroquinolones (levofloxacin) in cases of non-severe community-acquired pneumonia with concomitant disease in patients of 60 years and older — were equally highly effective and safe.